

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**CanSino Biologics Inc.**  
**康希諾生物股份公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6185)**

**INSIDE INFORMATION**  
**RECOMBINANT COVID-19 VACCINE (ADENOVIRUS TYPE 5 VECTOR)**  
**FOR INHALATION**  
**INCLUDED FOR EMERGENCY USE AS BOOSTER VACCINE IN CHINA**

This announcement is made by CanSino Biologics Inc. (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The Company is pleased to announce that, as proposed by the National Health Commission of the People's Republic of China (the “**PRC**”) and approved by the National Medical Products Administration of the PRC (the “**NMPA**”) upon demonstration, the Company's Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation (the “**Ad5-nCoV for Inhalation**”) has been included for emergency use as a booster vaccine in the PRC. Further purchases by relevant national authorities, if any, will have certain positive effects on the results of the Company.

Ad5-nCoV for Inhalation is a genetic engineered inhaled vaccine to prevent COVID-19 disease, which can not only stimulate humoral and cellular immunity, but also induce mucosal immunity to achieve triple comprehensive protection efficiently without intramuscular injection. Ad5-nCoV for Inhalation has unique advantages of safety, effectiveness, painlessness, convenience and availability. As announced by the Company on March 23, 2021, the clinical trial application for the Ad5-nCoV for Inhalation has been approved by the NMPA.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**CanSino Biologics Inc.**  
**Xuefeng YU**  
*Chairman*

Hong Kong, September 4, 2022

*As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive directors.*